Landmark study offering new hope for the treatment of people living with peanut allergies

Allergies are commonly believed to have no cure. Given a large percentage of the population experiences various allergies, with peanut allergy the number one cause of allergy-induced fatalities, it was only a matter of time before scientists chose to explore ways to treat the serious health problem. Aimmune Therapeutics-funded study (PALISADE) involved almost 500 participants…

Read More

Australian-developed coeliac disease vaccine fast-tracked by the FDA

A vaccine for coeliac disease could soon be made available with the Australian-developed immunisation gaining fast-track designation from America’s Food and Drug Administration. ImmusanT’s Nexvax2, developed at the Walter and Eliza Hall Institute (WEHI) in Victoria, is set for a prompt review at the completion of its trial phases. Currently phase two, involving 150 patients…

Read More

Clinical trial spurs search for more Progeria children

To coincide with a new Progeria clinical trial, the campaign to locate more children across the globe living with the rare and fatal rapid-ageing condition has begun. The search is timely, as approximately 40 children from around the world travel to Boston, Massachusetts, in the United States over the next few months to take part…

Read More